Literature DB >> 6711309

Analysis of the immune response to papain digestion products of tetanus toxin.

T B Helting, H H Nau.   

Abstract

Tetanus toxin was degraded by papain and the previously characterized Fragment B and Fragment C were isolated. The induction of protective immunity against tetanus toxin was subsequently investigated in two animal models using Fragment B and Fragment C, as well as conventional tetanus toxoid for comparison. In guinea pigs, Fragment B showed an immunizing potency similar to that recorded for an equal amount of tetanus toxoid, whereas Fragment C was considerably less efficient, on an equal weight basis. In contrast, mice immunized with Fragment C reached a protection level similar to that achieved after immunization with the complete tetanus toxoid antigen. In both animal models, Fragments B and C acted in a synergistic fashion when injected together. Analysis of sera from guinea pigs using ELISA, after administration of a low dose of tetanus immunogen corroborated these results. The data indicate that antigenic determinants in distinct regions of the toxin molecule independently may induce antibodies neutralizing the lethal action of tetanus toxin. The immune response to the complete toxoid antigen may be subject to influence by intramolecular competition between antigenic determinants. The immunogenicity of the fragments as measured by the protection rate after active immunization may depend upon the animal species used.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6711309     DOI: 10.1111/j.1699-0463.1984.tb00052.x

Source DB:  PubMed          Journal:  Acta Pathol Microbiol Immunol Scand C        ISSN: 0108-0202


  16 in total

1.  Synthesis of tetanus toxin fragment C in insect cells by use of a baculovirus expression system.

Authors:  I G Charles; B C Rodgers; A J Makoff; S N Chatfield; D E Slater; N F Fairweather
Journal:  Infect Immun       Date:  1991-05       Impact factor: 3.441

2.  A conformational change of C fragment of tetanus neurotoxin reduces its ganglioside-binding activity but does not destroy its immunogenicity.

Authors:  Rui Yu; Shaoqiong Yi; Changming Yu; Ting Fang; Shuling Liu; Ting Yu; Xiaohong Song; Ling Fu; Lihua Hou; Wei Chen
Journal:  Clin Vaccine Immunol       Date:  2011-08-03

3.  Utility of recombinant fragment C for assessment of anti-tetanus antibodies in plasma.

Authors:  Girija Ramakrishnan; Karl Pedersen; Denis Guenette; Joyce Sink; Rashidul Haque; William A Petri; Joel Herbein; Carol A Gilchrist
Journal:  Diagn Microbiol Infect Dis       Date:  2015-02-07       Impact factor: 2.803

4.  Antibodies against the light chain of tetanus toxin in human sera.

Authors:  C S Lin; W H Habig; M C Hardegree
Journal:  Infect Immun       Date:  1985-07       Impact factor: 3.441

5.  Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal route.

Authors:  Easwaran Ravichandran; Fetweh H Al-Saleem; Denise M Ancharski; Mohammad D Elias; Ajay K Singh; Mohammad Shamim; Yujing Gong; Lance L Simpson
Journal:  Infect Immun       Date:  2007-03-19       Impact factor: 3.441

6.  Immunization of mice against tetanus with fragments of tetanus toxin synthesized in Escherichia coli.

Authors:  N F Fairweather; V A Lyness; D J Maskell
Journal:  Infect Immun       Date:  1987-11       Impact factor: 3.441

7.  Comparison of the abilities of different attenuated Salmonella typhimurium strains to elicit humoral immune responses against a heterologous antigen.

Authors:  S J Dunstan; C P Simmons; R A Strugnell
Journal:  Infect Immun       Date:  1998-02       Impact factor: 3.441

8.  Protective immunity against botulism provided by a single dose vaccination with an adenovirus-vectored vaccine.

Authors:  Mingtao Zeng; Qingfu Xu; Md Elias; Michael E Pichichero; Lance L Simpson; Leonard A Smith
Journal:  Vaccine       Date:  2007-09-05       Impact factor: 3.641

9.  Cloning, nucleotide sequencing, and expression of tetanus toxin fragment C in Escherichia coli.

Authors:  N F Fairweather; V A Lyness; D J Pickard; G Allen; R O Thomson
Journal:  J Bacteriol       Date:  1986-01       Impact factor: 3.490

10.  Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate.

Authors:  M P Byrne; T J Smith; V A Montgomery; L A Smith
Journal:  Infect Immun       Date:  1998-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.